BioNTech SE (NASDAQ: BNTX) stock fell -1.58% on Wednesday to $156.23 against a previous-day closing price of $158.73. With 0.61 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.86 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $158.76 whereas the lowest price it dropped to was $155.09. The 52-week range on BNTX shows that it touched its highest point at $369.63 and its lowest point at $117.08 during that stretch. It currently has a 1-year price target of $211.39.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BNTX was down-trending over the past week, with a drop of -5.26%, but this was up by 15.49% over a month. Three-month performance surged to 5.16% while six-month performance rose 2.36%. The stock lost -48.74% in the past year, while it has lost -38.59% so far this year. A look at the trailing 12-month EPS for BNTX yields 42.28 with Next year EPS estimates of 17.07. For the next quarter, that number is 7.53. This implies an EPS growth rate of -9.40% for this year and -51.69% for next year.
Float and Shares Shorts:
At present, 240.23 million BNTX shares are outstanding with a float of 215.11 million shares on hand for trading. On Oct 13, 2022, short shares totaled 2.21 million, which was 0.91% higher than short shares on Sep 14, 2022. In addition to Prof. Ugur Sahin M.D. as the firm’s Co-Founder, CEO & Chair of the Management Board, Dr. Ozlem Tureci M.D. serves as its Co-Founder, Chief Medical Officer & Member of Management Board.
Through their ownership of 15.47% of BNTX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 8.39% of BNTX, in contrast to 7.35% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in BNTX with 2.98% of the stake, Baillie Gifford & Co. holds 7,245,072 shares worth 7,245,072. A second-largest stockholder of BNTX, Temasek Holdings Pte Ltd., holds 4,378,022 shares, controlling over 1.80% of the firm’s shares. PRIMECAP Management Co. is the third largest shareholder in BNTX, holding 4,194,388 shares or 1.73% stake. With a 0.85% stake in BNTX, the Vanguard Capital Opportunity Fund is the largest stakeholder. A total of 2,076,166 shares are owned by the mutual fund manager. The iShares Biotechnology ETF, which owns about 0.62% of BNTX stock, is the second-largest Mutual Fund holder. It holds 1,494,720 shares valued at 205.73 million. PRIMECAP Odyssey Aggressive Growt holds 0.59% of the stake in BNTX, owning 1,423,462 shares worth 195.93 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BNTX since 15 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 8 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BNTX analysts setting a high price target of $312.02 and a low target of $142.84, the average target price over the next 12 months is $213.47. Based on these targets, BNTX could surge 99.72% to reach the target high and fall by -8.57% to reach the target low. Reaching the average price target will result in a growth of 36.64% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. BNTX will report FY 2022 earnings on 03/29/2023. Analysts have provided yearly estimates in a range of $40.19 being high and $31.50 being low. For BNTX, this leads to a yearly average estimate of $35.24. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. BioNTech SE surprised analysts by $3.59 when it reported $6.98 EPS against a consensus estimate of $3.38. The surprise factor in the prior quarter was -$0.61. Based on analyst estimates, the high estimate for the next quarter is $8.51 and the low estimate is $5.52. The average estimate for the next quarter is thus $7.40.